Sam Brusco, Associate Editor06.13.22
Ekso Bionics’ EksoNR robotic exoskeleton has earned U.S. Food and Drug Administration (FDA) 510(k) clearance to use with multiple sclerosis (MS) patients.
EksoNR is the latest generation device of Ekso’s widely used robotic exoskeleton. The FDA cleared it for stroke and spinal cord injury rehab in 2016 and for brain injury rehab in 2020. EksoNR is the first exoskeleton to receive an indication for MS.
“As a leader in early-to-market wearable robotic solutions for medical rehabilitation, we are committed to maximizing patient access to our technology,” Steven Sherman, chairman and CEO of Ekso Bionics told the press. “With the indications for use now expanded to include MS, the EksoNR has the potential to assist significantly more patients and improve patient mobility. We are excited to see the device benefit MS patients, providing critically needed rehabilitation solutions just as it has for patients suffering from stroke, spinal cord injury and acquired brain injury.”
MS disrupts the flow of information within the brain as well as between the brain and body. Symptoms can include neurological deficits, from vision impairment and fatigue to numbness and difficulty walking.
EksoNR is also CE marked. It’s used in over 375 rehabilitation centers globally.
EksoNR is the latest generation device of Ekso’s widely used robotic exoskeleton. The FDA cleared it for stroke and spinal cord injury rehab in 2016 and for brain injury rehab in 2020. EksoNR is the first exoskeleton to receive an indication for MS.
“As a leader in early-to-market wearable robotic solutions for medical rehabilitation, we are committed to maximizing patient access to our technology,” Steven Sherman, chairman and CEO of Ekso Bionics told the press. “With the indications for use now expanded to include MS, the EksoNR has the potential to assist significantly more patients and improve patient mobility. We are excited to see the device benefit MS patients, providing critically needed rehabilitation solutions just as it has for patients suffering from stroke, spinal cord injury and acquired brain injury.”
MS disrupts the flow of information within the brain as well as between the brain and body. Symptoms can include neurological deficits, from vision impairment and fatigue to numbness and difficulty walking.
EksoNR is also CE marked. It’s used in over 375 rehabilitation centers globally.